PMC:7784786 / 15748-16527 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"562","span":{"begin":38,"end":42},"obj":"Gene"},{"id":"563","span":{"begin":140,"end":144},"obj":"Gene"},{"id":"564","span":{"begin":287,"end":291},"obj":"Gene"},{"id":"565","span":{"begin":391,"end":395},"obj":"Gene"},{"id":"566","span":{"begin":186,"end":193},"obj":"Species"},{"id":"567","span":{"begin":734,"end":741},"obj":"Species"},{"id":"568","span":{"begin":346,"end":356},"obj":"Chemical"},{"id":"569","span":{"begin":194,"end":198},"obj":"Disease"},{"id":"570","span":{"begin":232,"end":260},"obj":"Disease"},{"id":"571","span":{"begin":602,"end":628},"obj":"Disease"},{"id":"572","span":{"begin":630,"end":640},"obj":"Disease"},{"id":"573","span":{"begin":642,"end":657},"obj":"Disease"},{"id":"574","span":{"begin":676,"end":683},"obj":"Disease"},{"id":"575","span":{"begin":742,"end":746},"obj":"Disease"}],"attributes":[{"id":"A562","pred":"tao:has_database_id","subj":"562","obj":"Gene:3569"},{"id":"A563","pred":"tao:has_database_id","subj":"563","obj":"Gene:3569"},{"id":"A564","pred":"tao:has_database_id","subj":"564","obj":"Gene:3569"},{"id":"A565","pred":"tao:has_database_id","subj":"565","obj":"Gene:3569"},{"id":"A566","pred":"tao:has_database_id","subj":"566","obj":"Tax:9606"},{"id":"A567","pred":"tao:has_database_id","subj":"567","obj":"Tax:9606"},{"id":"A568","pred":"tao:has_database_id","subj":"568","obj":"MESH:C000597346"},{"id":"A569","pred":"tao:has_database_id","subj":"569","obj":"MESH:D003643"},{"id":"A570","pred":"tao:has_database_id","subj":"570","obj":"MESH:D002318"},{"id":"A571","pred":"tao:has_database_id","subj":"571","obj":"MESH:D061325"},{"id":"A572","pred":"tao:has_database_id","subj":"572","obj":"MESH:D013927"},{"id":"A573","pred":"tao:has_database_id","subj":"573","obj":"MESH:D055370"},{"id":"A574","pred":"tao:has_database_id","subj":"574","obj":"MESH:D000860"},{"id":"A575","pred":"tao:has_database_id","subj":"575","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Our preliminary findings support that IL-6 levels correlated with the severity of the disease and that the antibody was capable of reducing IL-6 concentration in all three subjects. One patient died after subsequent respiratory and cardiovascular complications. In this particular case, IL-6 concentration was extremely elevated at the moment of itolizumab infusion. Although, the levels of IL-6 decreased during treatment, the values at 7 days kept still very high (above 300 pg/ml). There was a transient improvement of respiratory function but it was not enough. Presumably, the consequences of the hyperinflammatory syndrome (thrombosis, alveolar damage and severe tissue hypoxia) were irreversible at the moment of treatment and patient died as consequence of these factors."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T54","span":{"begin":676,"end":683},"obj":"Phenotype"}],"attributes":[{"id":"A54","pred":"hp_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/HP_0012418"}],"text":"Our preliminary findings support that IL-6 levels correlated with the severity of the disease and that the antibody was capable of reducing IL-6 concentration in all three subjects. One patient died after subsequent respiratory and cardiovascular complications. In this particular case, IL-6 concentration was extremely elevated at the moment of itolizumab infusion. Although, the levels of IL-6 decreased during treatment, the values at 7 days kept still very high (above 300 pg/ml). There was a transient improvement of respiratory function but it was not enough. Presumably, the consequences of the hyperinflammatory syndrome (thrombosis, alveolar damage and severe tissue hypoxia) were irreversible at the moment of treatment and patient died as consequence of these factors."}

{"project":"LitCovid-sentences","denotations":[{"id":"T139","span":{"begin":0,"end":181},"obj":"Sentence"},{"id":"T140","span":{"begin":182,"end":261},"obj":"Sentence"},{"id":"T141","span":{"begin":262,"end":366},"obj":"Sentence"},{"id":"T142","span":{"begin":367,"end":484},"obj":"Sentence"},{"id":"T143","span":{"begin":485,"end":565},"obj":"Sentence"},{"id":"T144","span":{"begin":566,"end":779},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our preliminary findings support that IL-6 levels correlated with the severity of the disease and that the antibody was capable of reducing IL-6 concentration in all three subjects. One patient died after subsequent respiratory and cardiovascular complications. In this particular case, IL-6 concentration was extremely elevated at the moment of itolizumab infusion. Although, the levels of IL-6 decreased during treatment, the values at 7 days kept still very high (above 300 pg/ml). There was a transient improvement of respiratory function but it was not enough. Presumably, the consequences of the hyperinflammatory syndrome (thrombosis, alveolar damage and severe tissue hypoxia) were irreversible at the moment of treatment and patient died as consequence of these factors."}